Two Indian nationals are facing charges in a federal court in Florida for their involvement in an alleged international operation to distribute counterfeit prescription drugs. The indictment was issued by a federal grand jury in the Middle District of Florida, with Swapandip Roy and Vicky Ramancha named alongside their co-conspirators. The charges include one count of conspiracy to commit smuggling and defraud the United States, three counts of smuggling, and two counts related to selling counterfeit drugs and holding them for sale.

Roy, who was extradited from Italy, made his initial court appearance on Tuesday in Tampa, Florida. If found guilty, both Roy and Ramancha could face a maximum penalty of 71 years in prison. The indictment alleges that their illegal activities spanned from at least July 2023 to April 2024.

Details of the Alleged Scheme

According to court documents, Roy and Ramancha reportedly sourced counterfeit Ozempic—commonly prescribed for diabetes—from unauthorised suppliers in China. The counterfeit products allegedly featured misleading packaging, including fake labels, package inserts, and needles designed to deceive customers into believing they were purchasing genuine Ozempic, approved by its manufacturer.

Despite a seizure of counterfeit Ozempic by the US Food and Drug Administration (FDA) in December 2023 and a public warning about the products, the alleged scheme purportedly continued. This raised significant concerns regarding the safety of the pharmaceutical supply chain in the United States.

Furthermore, the Justice Department’s Office of International Affairs played a crucial role in securing Roy’s continued detention following his arrest. His extradition from Italy was facilitated by an INTERPOL Red Notice, underscoring the gravity of the alleged crimes.

Statements from Authorities

Assistant Attorney General A. Tysen Duva of the Justice Department’s Criminal Division remarked on the situation, stating that counterfeit prescription drugs jeopardise the health and safety of Americans relying on the integrity of pharmaceutical products. He emphasised the agency’s determination to pursue anyone involved in deceiving consumers with counterfeit medications.

In addition, Assistant US Attorney Christopher Murray from the Middle District of Florida affirmed the department’s commitment to safeguarding the public from the dangers posed by counterfeit prescription drugs. He reiterated that efforts to prevent bad actors from compromising the pharmaceutical supply chain will continue vigorously.

Justin Green, Assistant Commissioner of the FDA’s Office of Criminal Investigations, highlighted the importance of maintaining a highly regulated wholesale distribution market. He stated that the introduction of counterfeit drugs into the American market puts consumers at considerable risk. Green underscored the collaborative efforts between the FDA and various federal agencies, foreign counterparts, and the private sector to protect the integrity of the nation’s drug supply.

Long or Short, get news the way you like. No ads. No redirections. Download Newspin and Stay Alert, The CSR Journal Mobile app, for fast, crisp, clean updates!

App Store –  https://apps.apple.com/in/app/newspin/id6746449540 

Google Play Store – https://play.google.com/store/apps/details?id=com.inventifweb.newspin&pcampaignid=web_share